Diabetes Type 2: ADA Guidelines & SGLT2/GLP-1

Clinical meaning

Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by the 'ominous octet' — eight distinct pathophysiological defects that contribute to hyperglycemia (as described by DeFronzo): 1. Insulin resistance in muscle: impaired glucose uptake due to defective GLUT4 translocation and post-receptor signaling abnormalities 2. Hepatic insulin resistance: failure to suppress gluconeogenesis and glycogenolysis, leading to excessive hepatic glucose output (the primary cause of fasting hyperglycemia) 3. Beta-cell dysfunction: progressive loss of insulin secretory capacity — beta-cell function is already reduced ~50% at the time of T2DM diagnosis and continues to decline at ~4% per year 4. Adipocyte insulin resistance: impaired lipogenesis and increased lipolysis release FFAs that worsen hepatic and muscle insulin resistance (lipotoxicity) 5. Incretin deficiency/resistance: reduced GLP-1 secretion and impaired GIP action reduce the 'incretin effect' (normally responsible for 50-70% of meal-stimulated insulin secretion) 6. Alpha-cell dysregulation: inappropriate glucagon secretion (normally suppressed by postprandial hyperglycemia) drives hepatic gluconeogenesis 7. Renal glucose reabsorption: upregulated SGLT2 transporters in the proximal tubule increase the renal threshold for glucosuria, reabsorbing more glucose back into the blood 8. CNS neurotransmitter dysfunction: hypothalamic insulin resistance reduces appetite suppression and impairs glucose counter-regulation

The ADA Standards of Care (updated annually) provide the evidence-based framework for T2DM management. The 2024 guidelines emphasize cardiorenal risk reduction beyond glycemic control: - HbA1c target: <7% for most adults (more stringent <6.5% for younger patients without hypoglycemia risk; less stringent <8% for elderly, limited life expectancy, extensive comorbidities) - BEYOND glycemic control: SGLT2 inhibitors and GLP-1 receptor agonists are recommended INDEPENDENT of HbA1c for patients with established ASCVD, heart failure, or CKD — their cardiorenal benefits are independent of glucose lowering - Weight management: increasingly central to T2DM treatment — tirzepatide (dual GIP/GLP-1 agonist) and semaglutide achieve 15-22% weight loss

Diagnosis & workup

Diagnostics & workup: - HbA1c: reflects average blood glucose over 2-3 months; diagnostic threshold ≥6.5%; target <7% for most adults; check every 3 months if not at goal, every 6 months if stable; can be falsely low (hemolytic anemia, blood loss, hemoglobinopathies) or falsely high (iron deficiency, splenectomy) - Fasting plasma glucose (FPG): ≥126 mg/dL on two occasions is diagnostic; correlates with hepatic glucose output (fasting hyperglycemia = hepatic insulin resistance) - 2-hour oral glucose tolerance test (OGTT): 75g glucose load; ≥200 mg/dL at 2 hours is diagnostic; most sensitive test for early T2DM and IGT; not commonly used in clinical practice due to inconvenience - Random plasma glucose ≥200 mg/dL with classic symptoms (polyuria, polydipsia, unexplained weight loss): sufficient for diagnosis on a single test without confirmation - Comprehensive metabolic panel including lipid panel: T2DM rarely occurs in isolation — screen for dyslipidemia (elevated triglycerides and small dense LDL are characteristic), assess renal function (eGFR guides medication selection), hepatic function (for metformin and statin use) - Urine albumin-to-creatinine ratio (UACR): screen annually for diabetic nephropathy; ≥30 mg/g = albuminuria (formerly 'microalbuminuria'); ≥300 mg/g = severely increased albuminuria; SGLT2 inhibitors are first-line for diabetic nephropathy - Dilated retinal examination: annual screening for diabetic retinopathy; GLP-1 agonists may transiently worsen retinopathy with rapid glucose reduction — monitor closely in patients with pre-existing retinopathy

Risk factors: - Obesity (BMI ≥30) — the strongest modifiable risk factor; visceral adiposity drives insulin resistance through adipokine dysregulation (increased TNF-alpha, decreased adiponectin, increased IL-6), ectopic fat deposition in liver and muscle, and chronic low-grade inflammation - Family history (first-degree relative with T2DM increases risk 2-6 fold; concordance rate in monozygotic twins is 70-90%, indicating strong genetic component with polygenic inheritance) - Ethnic predisposition: South Asian, Black, Hispanic, Indigenous, and Pacific Islander populations have 2-6 times higher T2DM prevalence — multifactorial (genetic variants, socioeconomic factors, dietary patterns) - Physical inactivity: exercise improves insulin sensitivity through GLUT4 upregulation, AMPK activation, and improved mitochondrial function — 150 min/week moderate activity reduces T2DM risk by 58% (DPP trial) - History of gestational diabetes (50% lifetime risk of developing T2DM within 5-10 years postpartum) - Polycystic ovarian syndrome (PCOS): 50-70% of women with PCOS develop insulin resistance; metformin is used for both PCOS and T2DM prevention - Prediabetes (HbA1c 5.7-6.4%, fasting glucose 100-125 mg/dL, 2-hour OGTT 140-199 mg/dL): annual progression to T2DM is 5-10% without intervention - Metabolic syndrome: central obesity + 2 of: triglycerides ≥150, HDL <40 (men)/<50 (women), BP ≥130/85, fasting glucose ≥100

Clinical meaning

Your next step on AGPCNP

Practice this topic

Review related lessons

AGPCNP CAT

Diagnosis & workup

Management

Prescribing & monitoring

Takeaways

Your next step on AGPCNP

Practice this topic

Review related lessons

AGPCNP CAT

Clinical meaning

Practice questions for this topic

Your next step on AGPCNP

Practice this topic

Review related lessons

AGPCNP CAT

Diagnosis & workup

Practice questions for this topic

Your next step on AGPCNP

Practice this topic

Review related lessons

AGPCNP CAT